Quest Diagnostics Incorporated: valuation
What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.
Cash-flow value and what the price assumes
Average of FY2023–FY2025 (cash from operations less capital spending), from the statements below.
Starts at revenue growth over the last three years, 3.7% a year (statements).
US Treasury 10-year yield on Nov 13, 2026: 5.15% (US Treasury).
Your assumption: the extra yearly return you want for holding shares rather than Treasuries. 5% is a round starting figure, not data.
Your assumption: long-run growth, usually near inflation. It must stay below the discount rate.
Debt less cash at the end of FY2025 (statements); negative means more cash than debt.
What today's price assumes
A market value of $27.8 B means free cash flow growing 14.3% a year for 10 years, then 2.5% for ever, at a 10.15% discount rate.
Revenue grew 3.7% a year over the last three years.
Against the market value, for other rates
Cash-flow value of the shares as a percentage above or below today's market value; your inputs in the middle.
| Discount rate ↓ / growth → | -1.26% | 1.24% | 3.74% | 6.24% | 8.74% |
|---|---|---|---|---|---|
| 8.15% | -68% | -57% | -44% | -28% | -8% |
| 9.15% | -75% | -66% | -55% | -42% | -26% |
| 10.15% | -80% | -73% | -64% | -53% | -40% |
| 11.15% | -85% | -78% | -70% | -61% | -50% |
| 12.15% | -88% | -82% | -76% | -67% | -58% |
On one scale
Bars: from the 25th to the 75th percentile multiple of the peers, the line at the median; dot: the cash-flow value with your inputs.
Your own DCF model
A full discounted-cash-flow model of Quest Diagnostics Incorporated, started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.
Open the DCF modelAgainst the industry Diagnostics and Research
Multiples of its companies with a market value at most 60 days old, times Quest Diagnostics Incorporated's own figures of FY2025.
| Multiple | Peers (25th / median / 75th) | The company | Applied to | Value (25th to 75th) | Companies |
|---|---|---|---|---|---|
| P/E | 30.2× / 35.9× / 69.4× | 24.6× | net income $992 M | $30.0 B to $68.8 B | 21 |
| Price to sales | 2.4× / 5.4× / 8.0× | 2.4× | revenue $11.0 B | $26.0 B to $88.4 B | 36 |
| Price to book | 2.7× / 6.9× / 14.0× | 3.9× | book equity $7.2 B | $19.5 B to $100.5 B | 34 |
Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.
Against its own history
Quest Diagnostics Incorporated's multiples at each month end with a market cap on file, Jan 2020 to Oct 2026, each against its own median.
P/E
26.2×Now above its median of 21.7×, in the top quarter of its range; range 8.9× to 26.2× over 30 months.
Price to sales
2.4×Now above its median of 1.9×, in the top quarter of its range; range 1.5× to 2.4× over 30 months.
Price to book
3.9×Now above its median of 3.0×, in the top quarter of its range; range 2.6× to 3.9× over 30 months.
as of Oct 30, 2026. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Oct 30, 2026.
The statements it starts from
USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.
| Fiscal year | Revenue | Net income | Cash from operations | Capital spending | Free cash flow | Net debt | Source |
|---|---|---|---|---|---|---|---|
| FY2025to Dec 31, 2025 | $11.0 B | $992 M | $1.9 B | $527 M | $1.4 B | $5.3 B | SEC annual report (10-K, 20-F) |
| FY2024to Dec 31, 2024 | $9.9 B | $871 M | $1.3 B | $425 M | $909 M | $5.7 B | SEC annual report (10-K, 20-F) |
| FY2023to Dec 31, 2023 | $9.3 B | $854 M | $1.3 B | $408 M | $864 M | $4.0 B | SEC annual report (10-K, 20-F) |
| FY2022to Dec 31, 2022 | $9.9 B | $946 M | $1.7 B | $404 M | $1.3 B | $3.7 B | SEC annual report (10-K, 20-F) |
| FY2021to Dec 31, 2021 | $10.8 B | $2.0 B | $2.2 B | $403 M | $1.8 B | $3.1 B | SEC annual report (10-K, 20-F) |
| FY2020to Dec 31, 2020 | $9.4 B | $1.4 B | $2.0 B | $418 M | $1.6 B | $2.9 B | SEC annual report (10-K, 20-F) |
Each figure as filed; the full statements with every line and its filing are on the company page. Market value $27.8 B on Oct 30, 2026.
How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.